CR20180104A - Inhibidores de ezh2 - Google Patents

Inhibidores de ezh2

Info

Publication number
CR20180104A
CR20180104A CR20180104A CR20180104A CR20180104A CR 20180104 A CR20180104 A CR 20180104A CR 20180104 A CR20180104 A CR 20180104A CR 20180104 A CR20180104 A CR 20180104A CR 20180104 A CR20180104 A CR 20180104A
Authority
CR
Costa Rica
Prior art keywords
compounds
ezh2 inhibitors
ezh2
zeste
hematological
Prior art date
Application number
CR20180104A
Other languages
English (en)
Inventor
Yvonne Yee Mai Yip
Esteban Domínguez
Anh-Quan Hannah Nguyen
Mary Margaret Mader
Prado Miriam Filadelfa Del
Michael Enrico Richett
Michael John Rodríguez
Deqi Guo
Kuo-Long Yu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20180104A publication Critical patent/CR20180104A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos que inhiben la actividad de la histona lisina metiltransferasa, Potenciador del Homólogo Zeste 2 (EZH2, por sus siglas en inglés), composiciones farmacéuticas que comprenden los compuestos, y métodos para usar los compuestos para tratar cáncer, tales como tumores hematológicos y sólidos
CR20180104A 2015-08-27 2016-08-22 Inhibidores de ezh2 CR20180104A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382433 2015-08-27
EP15382615 2015-12-11
PCT/US2016/047989 WO2017035060A1 (en) 2015-08-27 2016-08-22 Inhibitors of ezh2

Publications (1)

Publication Number Publication Date
CR20180104A true CR20180104A (es) 2018-04-24

Family

ID=56801893

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180104A CR20180104A (es) 2015-08-27 2016-08-22 Inhibidores de ezh2

Country Status (31)

Country Link
US (1) US9718838B2 (es)
EP (1) EP3341379B1 (es)
JP (1) JP6704040B2 (es)
KR (1) KR20180030704A (es)
CN (1) CN107922434B (es)
AU (1) AU2016313541A1 (es)
BR (1) BR112018003108A2 (es)
CA (1) CA2994428A1 (es)
CO (1) CO2018002033A2 (es)
CR (1) CR20180104A (es)
CY (1) CY1122364T1 (es)
DK (1) DK3341379T3 (es)
DO (1) DOP2018000058A (es)
EC (1) ECSP18014798A (es)
ES (1) ES2756603T3 (es)
HR (1) HRP20192101T1 (es)
HU (1) HUE047630T2 (es)
IL (1) IL257061A (es)
LT (1) LT3341379T (es)
MD (1) MD3341379T2 (es)
ME (1) ME03650B (es)
MX (1) MX2018002484A (es)
PE (1) PE20181025A1 (es)
PH (1) PH12018500423A1 (es)
PL (1) PL3341379T3 (es)
PT (1) PT3341379T (es)
RS (1) RS59615B1 (es)
SI (1) SI3341379T1 (es)
TN (1) TN2018000058A1 (es)
TW (1) TW201718598A (es)
WO (1) WO2017035060A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1173201E (pt) * 1999-04-22 2005-08-31 Biogen Idec Inc Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
SG11201809560QA (en) * 2016-05-05 2018-11-29 Glaxosmithkline Ip No 2 Ltd Enhancer of zeste homolog 2 inhibitors
CN109312407A (zh) * 2016-06-08 2019-02-05 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
NZ766447A (en) 2018-01-31 2021-12-24 Mirati Therapeutics Inc Prc2 inhibitors
CN111601791B (zh) * 2018-04-24 2022-10-04 上海海雁医药科技有限公司 Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
WO2020219448A1 (en) 2019-04-22 2020-10-29 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
JP7541538B2 (ja) 2019-06-05 2024-08-28 ミラティ セラピューティクス，インク． 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体
CN114269727A (zh) * 2019-08-16 2022-04-01 西克拉塞尔有限公司 制备嘧啶并二氮杂环庚三烯衍生物的方法
CN116239519A (zh) * 2023-02-20 2023-06-09 安徽峆一药业股份有限公司 一种(2-苄氧基-4,6-二甲基吡啶-3-基)甲醇的合成方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504342A (ja) * 2000-07-24 2004-02-12 ファルマシア・アンド・アップジョン・カンパニー 極めて水不溶性の脂肪親和性薬剤用の自己乳化性ドラッグデリバリーシステム
JP2004524277A (ja) * 2000-10-20 2004-08-12 ブリストル−マイヤーズ スクイブ ファーマ カンパニー アシルセミカルバジド及びサイクリン依存性キナーゼ（ｃｄｋ）阻害剤としてのその使用
CN100441176C (zh) * 2001-09-24 2008-12-10 杰西·L·S·奥 测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物
JP2006521794A (ja) 2003-02-14 2006-09-28 スミスクライン・ビーチャム・コーポレイション Ｋｓｐ発現と相関関係にある示差発現核酸
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インダゾール
EA023788B1 (ru) 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5908493B2 (ja) 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インドール
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
WO2013039988A1 (en) 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
CA2854447A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2953941B1 (en) 2013-02-11 2017-04-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
KR102587175B1 (ko) * 2012-03-12 2023-10-06 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
CN104350311A (zh) 2012-04-12 2015-02-11 纳幕尔杜邦公司 罐龙头
JP6340361B2 (ja) 2012-04-13 2018-06-06 エピザイム，インコーポレイティド がんを処置するための組合せ治療
IL296199B2 (en) 2012-04-13 2024-12-01 Eisai R&D Man Co Ltd Salt form of a human hi stone methyltransf erase ezh2 inhibitor
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2013181462A1 (en) * 2012-05-31 2013-12-05 Amgen Inc. Use of amg 900 for the treatment of cancer
CA2884848C (en) 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
AU2013331380B2 (en) 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
AU2013371541B2 (en) 2012-12-13 2016-10-13 Glaxosmithkline Llc Enhancer of Zeste Homolog 2 inhibitors
WO2014100080A1 (en) 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
WO2014100665A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014100646A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9505745B2 (en) 2013-04-30 2016-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
ES2640386T3 (es) 2013-07-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Potenciador de inhibidores del homólogo Zeste 2
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US20160228447A1 (en) 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
US9822103B2 (en) 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015104677A1 (en) 2014-01-10 2015-07-16 Piramal Enterprises Limited Heterocyclic compounds as ezh2 inhibitors
HUE049417T2 (hu) 2014-03-17 2020-09-28 Daiichi Sankyo Co Ltd 1,3-benzodioxol származékok mint EZHl és/vagy EZH2 inhibitorok
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
LT3157527T (lt) 2014-06-17 2023-07-25 Epizyme, Inc. Ezh2 inhibitoriai, skirti limfomos gydymui
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
EA036889B1 (ru) 2014-06-19 2021-01-12 Мемориал Слоан-Кеттеринг Кэнсер Сентер Биомаркеры ответа на ингибиторы ezh2
US20170217941A1 (en) 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CN107148419A (zh) 2014-10-28 2017-09-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2抑制剂
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
WO2016130396A1 (en) 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2016140501A1 (en) 2015-03-04 2016-09-09 Kainos Medicine, Inc. Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
TW201708210A (zh) 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑

Also Published As

Publication number Publication date
TN2018000058A1 (en) 2019-07-08
PL3341379T3 (pl) 2020-05-18
EP3341379B1 (en) 2019-10-09
AU2016313541A1 (en) 2018-02-15
TW201718598A (zh) 2017-06-01
LT3341379T (lt) 2019-12-10
ME03650B (me) 2020-07-20
EP3341379A1 (en) 2018-07-04
IL257061A (en) 2018-03-29
DOP2018000058A (es) 2018-03-30
WO2017035060A1 (en) 2017-03-02
SI3341379T1 (sl) 2019-11-29
JP2018530527A (ja) 2018-10-18
BR112018003108A2 (pt) 2018-09-25
MX2018002484A (es) 2018-06-15
CO2018002033A2 (es) 2018-05-21
CA2994428A1 (en) 2017-03-02
HUE047630T2 (hu) 2021-12-28
JP6704040B2 (ja) 2020-06-03
DK3341379T3 (da) 2019-12-02
PT3341379T (pt) 2019-12-16
PH12018500423A1 (en) 2018-08-29
ES2756603T3 (es) 2020-04-27
KR20180030704A (ko) 2018-03-23
HRP20192101T1 (hr) 2020-02-21
MD3341379T2 (ro) 2020-01-31
ECSP18014798A (es) 2018-04-30
CN107922434A (zh) 2018-04-17
RS59615B1 (sr) 2020-01-31
CN107922434B (zh) 2020-06-19
US20170066780A1 (en) 2017-03-09
PE20181025A1 (es) 2018-06-27
US9718838B2 (en) 2017-08-01
CY1122364T1 (el) 2021-01-27

Similar Documents

Publication Publication Date Title
DOP2018000058A (es) Inhibidores de ezh2
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
CO2017011183A2 (es) Inhibidores de indolamina-2,3-dioxigenasa composiciones que los contienen y métodos de preparación
CO2017011484A2 (es) Inhibidores de bromodominio
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CR20160229A (es) Inhibidires de bromodominio
CO2018004750A2 (es) Composiciones para inhibir la actividad arginasa
PH12015502028A1 (en) Ido inhibitors
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
CL2017001046A1 (es) Inhibidoes del bromodominio
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
EA201890052A1 (ru) Регуляторы nrf2
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CR20180560A (es) Ésteres de oxaboral y sus usos
CR20180521A (es) Inhibidores del potenciador del homólogo zeste 2
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
CR20150593A (es) Potenciador de inhibidores del homólogo de zeste